Dianthus Therapeutics Inc.
$ 89.82
-1.61%
23 Apr - close price
- Market Cap 4,970,629,000 USD
- Current Price $ 89.82
- High / Low $ 92.36 / 89.14
- Stock P/E N/A
- Book Value 11.41
- EPS -4.20
- Next Earning Report 2026-05-11
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.25 %
- ROE -0.38 %
- 52 Week High 96.50
- 52 Week Low 16.64
About
Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company that designs, develops, and delivers novel monoclonal antibodies for people living with severe autoimmune and inflammatory diseases. The company is headquartered in New York, New York.
Analyst Target Price
$125.46
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-03-09 | 2025-11-05 | 2025-08-07 | 2025-05-07 | 2025-03-19 | 2024-11-07 | 2024-08-08 | 2024-05-09 | 2024-03-21 | 2023-11-09 | 2023-09-18 | 2023-05-11 |
| Reported EPS | -1.43 | -0.97 | -0.88 | -0.82 | -0.81 | -0.72 | -0.51 | -0.54 | -0.71 | -3.78 | -0.8663 | -0.47 |
| Estimated EPS | -1.0314 | -0.55 | -0.53 | -0.71 | -0.76 | -0.59 | -0.55 | -0.44 | -1.01 | -0.56 | -3.04 | -0.4 |
| Surprise | -0.3986 | -0.42 | -0.35 | -0.11 | -0.05 | -0.13 | 0.04 | -0.1 | 0.3 | -3.22 | 2.1737 | -0.07 |
| Surprise Percentage | -38.6465% | -76.3636% | -66.0377% | -15.493% | -6.5789% | -22.0339% | 7.2727% | -22.7273% | 29.703% | -575% | 71.5033% | -17.5% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-11 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | -1.17 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: DNTH
2026-04-23 14:09:27
This article examines the recent performance of Dianthus Therapeutics, Inc. (DNTH), which saw its stock price increase by 5.6%. It questions whether this rise indicates a continued strengthening trend for the company's shares.
2026-04-23 05:47:00
Dianthus Therapeutics Inc (NASDAQ: DNTH) has received favorable news from the FDA regarding its claseprubart clinical trials, as the regulator has dropped certain screening and testing requirements. This change is expected to ease patient enrollment and may positively impact the drug's labeling. William Blair maintains an Outperform rating on DNTH, citing strong interim results from the CAPTIVATE trial and the potential for claseprubart to treat autoimmune disorders, with key trial results expected in mid-2026 and 2028.
2026-04-20 12:39:29
Ryan Savitz, CFO and Chief Business Officer of Dianthus Therapeutics, has sold his entire direct holding of 8,224 company shares for approximately $739,000. This transaction was part of a pre-arranged trading plan established in December 2025. Following the sale, Savitz no longer directly owns common stock but retains a substantial 71,776 stock options.
2026-04-19 13:10:06
Dianthus Therapeutics' CFO, Ryan Savitz, sold 8,224 shares for $739,000 through an option exercise and immediate sale under a Rule 10b5-1 plan. This transaction, which reduced his direct ownership to zero, is characterized as routine liquidity management rather than a strategic shift. Despite the sale, Savitz retains options for 71,776 additional shares, and the company recently saw its stock jump after positive phase 3 clinical trial results and a significantly upsized secondary offering.
2026-04-18 09:08:47
Clear Street has initiated a "Buy" rating on Dianthus Therapeutics, Inc. (DNTH) and set a price target of $100. This indicates an optimistic outlook from the firm regarding Dianthus Therapeutics' future stock performance.
2026-04-16 10:09:48
Dianthus Therapeutics (DNTH) recently raised US$719 million through a public offering, and an executive sold shares under a Rule 10b5-1 plan. Despite the insider sale, favorable FDA trial updates and promising interim data for its lead therapies have led to reaffirmed positive analyst coverage. Investors are now evaluating how this significant capital raise impacts the company's investment outlook, given its focus on complement-focused pipeline and ongoing losses.
